Prostate cancer spreads to bone far more often than to any other site. In a large population-based analysis of nearly 75,000 men with metastatic prostate cancer, bone was the destination in about 84% of cases, with distant lymph nodes, liver, and the chest each involved in roughly one in ten patients.1PubMed. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis That lopsided preference for the skeleton shapes nearly everything about how metastatic prostate cancer is monitored, treated, and experienced. But the picture is more layered than “it goes to the bones,” and understanding which bones, which organs, and in what order matters both for prognosis and for the growing menu of treatments that can target individual metastatic spots.
Bone Is the Dominant Destination
The skeleton is not just the most common metastatic site for prostate cancer; it is overwhelmingly so. The spine, pelvis, and ribs absorb the bulk of these deposits. In one imaging study of over 100 men with bone metastases, nearly 29% of individual lesions appeared in the ribs, about 15% in the thoracic spine, 14% in the ilium (the broad wing of the pelvis), and 8% in the lumbar spine.2Nuclear Medicine Communications. Study on the distribution features of bone metastases in prostate cancer When the disease had produced only a handful of bone lesions, the spine and pelvis accounted for the vast majority of them, suggesting those areas are the first stop rather than a late-stage spillover.
This clustering around the central skeleton is not random. A network of veins called the vertebral venous plexus connects the pelvic veins directly to the veins running alongside the spine. Unlike the main venous system, these vessels lack valves, so blood can flow backward through them, especially when pressure in the abdomen rises. Prostate cancer cells can ride that current straight from the pelvis into the vertebral column without first passing through the lungs or liver.3PubMed. Clinical significance of the vertebral vein in prostate cancer metastasis Animal experiments have confirmed the route: when researchers blocked the main abdominal vein in mice and injected tumor cells, the cells reliably ended up growing in the lumbar spine.4PubMed. Models for cancer skeletal metastasis: a reappraisal of Batson’s plexus
Anatomy gets the cancer cells to bone, but the bone environment keeps them there. Bone is constantly being broken down and rebuilt by two cell types, and that active remodeling releases growth factors that prostate cancer cells exploit. Chemical signals produced by bone cells, particularly a molecule called CXCL12, essentially beckon prostate cancer cells that carry a matching receptor on their surface.5Endocrine-Related Cancer. Prostate cancer and bone: clinical presentation and molecular mechanisms Once settled, the cancer cells hijack the remodeling cycle, stimulating new bone formation and bone destruction in a disorganized way that weakens the skeleton even as it appears dense on imaging.6PubMed Central. Prostate Cancer and Bone Metastases: The Underlying Mechanisms That combination of an easy travel route and a welcoming microenvironment explains why bone metastasis is so disproportionately common.
What Bone Metastases Actually Do to You
On scans, prostate cancer bone lesions usually look dense and white, giving the impression that the bone is being strengthened. The reality is the opposite. Underneath that new bone formation, aggressive bone-eating activity is happening simultaneously. Markers of bone breakdown are elevated in these patients, and that underlying destruction is independently tied to a higher risk of fractures, disease progression, and death.7PubMed Central. Treatment and prevention of bone complications from prostate cancer The practical consequences are severe: bone pain that can become debilitating, pathological fractures that happen during ordinary activities, and spinal cord compression when vertebral lesions collapse or expand into the spinal canal.
Spinal cord compression is one of the most feared complications. When vertebral metastases press on the spinal cord, the result can range from leg weakness to complete paralysis. In one series, more than half the patients presenting with spinal cord compression were already unable to walk, and some were fully paraplegic.8PubMed. Spinal cord compression in metastatic prostate cancer Early recognition and treatment make a dramatic difference in preserving mobility, which is why new or worsening back pain in someone with known prostate cancer is treated as an urgent symptom.
Lymph Node Spread and Its Geography
Lymph nodes in the pelvis are often the first non-bone site where prostate cancer turns up. The internal iliac and obturator nodes sit closest to the prostate and tend to be the earliest involved. In a surgical mapping study of men with high-risk disease, the obturator nodes were positive in about 89% of node-positive patients, the external iliac nodes in 83%, and the common iliac nodes in 77%.9PubMed. Lymphatic spread of nodal metastases in high-risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum A clear stepwise pattern emerged: the cancer climbed from lower pelvic nodes to common iliac nodes and then into the retroperitoneal nodes along the aorta. Crucially, no patient with negative common iliac nodes had cancer in the retroperitoneal nodes, suggesting that spread follows a predictable ladder rather than skipping rungs.
This geography matters for both surgery and radiation planning. Standard pelvic lymph node dissections capture most of the likely positive nodes, but not all. In one sentinel-node study, a standard extended dissection would have correctly identified disease in the vast majority of patients yet would have removed all positive nodes in only about three-quarters of them. Adding the presacral region to the dissection improved those numbers.10PubMed. Mapping of pelvic lymph node metastases in prostate cancer A similar story plays out with radiation: imaging with specialized MRI found that over half of node-positive patients had at least one positive node outside the standard radiation target volume, most commonly in the proximal common iliac, pararectal, and para-aortic regions.11PubMed. Geographical distribution of lymph node metastases on MR lymphography in prostate cancer patients These findings have pushed surgeons and radiation oncologists to expand the territory they cover.
Visceral Metastases and Why the Organ Matters for Prognosis
When prostate cancer reaches organs beyond bone and lymph nodes, prognosis changes substantially, and it depends heavily on which organ is involved. Autopsy studies show the lungs are the second most common extranodal site after bone, found in roughly 46% of men who die from the disease.12PubMed Central. Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies Lung metastases during life are detected less often than that autopsy figure suggests, partly because small lung deposits can be clinically silent for a long time.
Among visceral sites, the lungs carry the least grim prognosis. Patients with metastases only in the lungs had a median survival of about 33 months in a large survival analysis, and when those lung-only metastases were accompanied by lymph node involvement rather than bone disease, median survival stretched to nearly 57 months.13PubMed. Overall Survival of Metastatic Prostate Cancer Patients According to Location of Visceral Metastatic Sites That is strikingly different from the outcomes with liver or brain involvement, where median survival hovered around 15 to 16 months regardless of what other sites were affected.13PubMed. Overall Survival of Metastatic Prostate Cancer Patients According to Location of Visceral Metastatic Sites
Liver metastases deserve special attention. They appear in an estimated 3 to 10% of men with treatment-resistant metastatic prostate cancer at baseline, but that number climbs to 20 to 30% in men who have been through newer hormonal treatments, suggesting that therapeutic pressure may push the cancer toward the liver.14Nature Reviews Urology. From biology to the clinic — exploring liver metastasis in prostate cancer Molecularly, liver lesions tend to look different from the typical prostate cancer: they are enriched for low androgen receptor activity, neuroendocrine features, and high genomic instability, all hallmarks of a cancer that has found ways to survive without the hormonal fuel that most prostate cancers depend on.14Nature Reviews Urology. From biology to the clinic — exploring liver metastasis in prostate cancer This aggressive biology helps explain why liver metastases carry worse outcomes than lung metastases.15PubMed Central. Treatment-Refractory, Castration-Resistant Prostate Cancer With Liver Metastasis: A Promising Modality of Therapy
Brain Metastases Are Rare but Serious
Prostate cancer spreading to the brain is uncommon. A large single-institution review found brain metastases confirmed by imaging or autopsy in under 1% of all prostate cancer patients.16PubMed. Brain metastasis from prostate carcinoma: The M. D. Anderson Cancer Center experience These cases tend to appear late, often after hormone treatments have failed, and survival is short: untreated patients had a median survival of one month, while radiation therapy extended that to about three and a half months.16PubMed. Brain metastasis from prostate carcinoma: The M. D. Anderson Cancer Center experience Because prostate cancer so rarely reaches the brain, routine brain scans are not recommended for most patients with metastatic disease.17PubMed. Cystic prostate metastases to the brain parenchyma: report of two cases and review of the literature
A systematic review noted that failure of hormone-blocking therapy may open the door to brain spread by allowing the cancer to evolve into forms that are no longer dependent on androgens and can thrive in new environments.18PubMed Central. The Clinical, Diagnostic, Therapeutic, and Prognostic Characteristics of Brain Metastases in Prostate Cancer: A Systematic Review This parallels the pattern seen with liver metastases, where treatment-resistant disease becomes biologically more aggressive and starts colonizing sites it previously could not reach.
Unusual Destinations
Beyond the common sites, prostate cancer occasionally turns up in surprising places. A 10-year review at one institution categorized “atypical” metastases and found that even within this unusual category, the lungs, pleura, and liver dominated, followed by lymph nodes above the diaphragm and the adrenal glands.19PubMed. Atypical metastases from prostate cancer: 10-year experience at a single institution Spread to the skin is documented but extremely rare, typically appearing as firm nodules that can be mistaken for other skin conditions.20PubMed Central. Cutaneous Metastasis of Prostate Adenocarcinoma: A Rare Presentation of a Common Disease Even rarer is peritoneal spread with massive fluid accumulation in the abdomen, a presentation more commonly associated with ovarian or gastrointestinal cancers.21Journal of Advanced Research. An unusual presentation of a patient with advanced prostate cancer, massive ascites and peritoneal metastasis: Case report and literature review
These atypical presentations matter because they can delay diagnosis. A doctor who sees an adrenal mass or a skin nodule may not immediately think of prostate cancer as the source, especially if the patient has not yet been diagnosed with prostate disease or if PSA levels have been treated and suppressed. Knowing that prostate cancer can, in uncommon cases, show up far from its usual territory helps clinicians keep it on the differential.
How Recurrence Patterns Differ After Treatment
When prostate cancer comes back after initial treatment, where it reappears depends partly on the original risk category. In men treated with radiation, the prostate bed itself was the most common first site of recurrence across all risk groups, but bone was the most common distant site, accounting for roughly a third of clinically detected recurrences. Pelvic lymph nodes appeared in about one in five, and abdominal lymph nodes in about one in ten.22PubMed Central. Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer Researchers found patients fell into distinct relapse patterns: some recurred only locally, some had a strong tendency toward bone, some toward lymph nodes, and some spread to multiple organs.
Among men who had positive lymph nodes at surgery and then recurred, skeletal recurrence was the single most common pattern, appearing in about 42% of those who relapsed. Visceral recurrence occurred in about 14%. The survival implications were dramatic: five-year cancer-specific survival was nearly 80% for those with local or nodal recurrence but dropped to roughly 51% for skeletal recurrence and 35% for visceral recurrence.23PubMed. Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival The timing of relapse also varies: local recurrences tend to appear later, around five years after treatment, while distant metastases to bone or distant lymph nodes show up sooner, typically within three to four years.24International Journal of Radiation Oncology, Biology, Physics. Patterns of Relapse Following Radiation Therapy of Intermediate-Risk Prostate Cancer in the PROFIT Randomized Trial
Finding Metastases Earlier With Modern Imaging
How well you can find metastatic disease has changed dramatically with the arrival of PSMA PET-CT, a scan that targets a protein found on most prostate cancer cells. Older imaging approaches like bone scans and conventional CT miss small deposits, especially in lymph nodes. PSMA PET-CT has improved detection of both regional and distant spread and now plays a role in initial staging, identifying recurrence after treatment, and guiding targeted therapy to individual metastases.25PubMed Central. PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer
For lymph node metastases specifically, the sensitivity of PSMA PET-CT varies widely across studies, from around a third to over 96%, but specificity is consistently high, generally above 82%. For bone metastases, its performance has been described as outstanding.26PubMed Central. 68Ga-PSMA PET/CT for the evaluation of metastasis in patients with prostate cancer: A systematic review and meta-analysis Even standard prostate MRI has shown surprising ability to catch bone metastases incidentally: in newly diagnosed men, MRI picked up bone lesions with over 95% sensitivity, though most of those lesions were in the pelvis and lumbar spine, which is where the MRI was already looking.27AJR Am J Roentgenol. Identification of Bone Metastasis With Routine Prostate MRI: A Study of Patients With Newly Diagnosed Prostate Cancer
Better imaging has also given rise to the concept of oligometastatic disease, where only a small number of metastatic spots are visible. This category matters because it opens the door to treating each lesion directly rather than relying solely on systemic therapy.
Treating Individual Metastatic Spots
When imaging picks up only a few metastases, particularly if they appear months or years after initial treatment rather than at diagnosis, targeted treatment of those specific lesions is increasingly an option. Stereotactic body radiation, which delivers a high dose of radiation precisely to a small area, has shown high rates of local control with minimal side effects in men with a handful of recurrent metastases.28PubMed. Use of stereotactic body radiation therapy for oligometastatic recurrent prostate cancer: A systematic review One potential benefit is delaying the start of hormone therapy, which carries its own burden of side effects. However, most patients in these studies eventually developed new metastatic spots elsewhere within about 15 months, so targeted treatment is not a cure for the underlying metastatic potential.29PubMed. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography
Randomized trials have supported the approach for men with a limited number of metastases that appear after the original cancer was treated, and the field is actively working to define who benefits most and whether combining targeted radiation with systemic therapy improves outcomes further.30Nature Reviews Urology. Oligometastatic prostate cancer — bridging the gap between localized and metastatic disease The emergence of PSMA PET-CT has been a key enabler here: earlier detection of small recurrences means there is a window for targeted treatment that simply did not exist when metastases were only found once they had grown large enough to appear on conventional scans.
Genetic Factors That Influence Where and How Aggressively It Spreads
Not every prostate cancer has the same metastatic potential. Certain inherited gene mutations, particularly in BRCA2, have been linked to more aggressive cancers that are more likely to spread beyond the prostate.31PubMed. GNL3 and SKA3 are novel prostate cancer metastasis susceptibility genes Research has also identified additional genes associated with aggressive behavior and lower disease-free survival in large patient datasets. This is relevant beyond academic interest: men whose tumors carry these mutations may be candidates for more intensive surveillance or earlier systemic treatment.
Circulating tumor cells also offer a window into metastatic risk. These cells can be found in the bloodstream even in men whose cancer appears localized on imaging, and tumor cells have been detected in the bone marrow of men without clinical evidence of distant spread.32PubMed Central. Circulating Tumor Cells in Prostate Cancer Diagnosis and Monitoring: An Appraisal of Clinical Potential Their presence in bone marrow has been correlated with a higher rate of PSA relapse after treatment, hinting that micro-metastatic seeding can happen long before it becomes visible on any scan. This is part of why prostate cancer can recur in bone years after seemingly successful treatment of the primary tumor: the seeds were already planted.